RMDS&P 500

ResMed SEC filings, summarized

We read every ResMed 8-K filing and insider trade the night it hits SEC EDGAR, and turn it into a two-minute plain-English summary.

Track RMD in your inbox

Add ResMed to your watchlist — free, every morning.

Subscribe free

Recent filings

Form 4 · Insider TradeOctober 8, 2026

ResMed CEO Michael Farrell sells $1.13M in stock

Michael J. Farrell, ResMed’s chairman and CEO and a director, sold 4,991 shares of common stock on Oct. 7 at $226.33 per share, for approximately $1.13…

Form 4 · Insider TradeSeptember 10, 2026

ResMed CEO Michael Farrell sells $1.1M in stock

Michael J. Farrell, ResMed’s chairman and CEO and a director, sold 4,991 shares of common stock on Sept. 8 at $222.44 per share, for approximately $1.11…

8-KSeptember 1, 2026

ResMed starts $450 million accelerated share repurchase with Citibank

ResMed entered into an accelerated share repurchase agreement with Citibank on August 31, 2026, and will pay $450 million on September 3, funded by proceeds…

8-KAugust 17, 2026

ResMed appoints Carol Burt as lead director as Ron Taylor plans retirement

ResMed announced that Carol Burt, a board member since 2013 and current Nominating and Governance Committee chair, will become lead director on November 15,…

8-KAugust 17, 2026

ResMed Names Carol Burt Lead Director as Ron Taylor Plans Board Retirement

ResMed said Carol Burt will become lead director on November 15, 2026, succeeding Ron Taylor, who will retire from the board after more than 21 years of…

8-KAugust 17, 2026

ResMed replaces KPMG with PwC as independent auditor

ResMed dismissed KPMG on August 13, 2026, and appointed PricewaterhouseCoopers LLP as its independent registered public accounting firm for the fiscal year…

Form 4 · Insider TradeAugust 11, 2026

ResMed CEO Michael Farrell sells $1.03M in stock

ResMed Chairman and CEO and Director Michael J. Farrell sold 4,991 shares of common stock on Aug. 7 at $205.69 per share, for approximately $1.03 million.…

8-KJanuary 29, 2026

ResMed filed an 8‑K (Item 9.01) attaching a press release dated Jan 29, 2026 reporting results of…

ResMed filed an 8‑K (Item 9.01) attaching a press release dated Jan 29, 2026 reporting results of operations (Exhibit 99.1). Signed by CFO Brett Sandercock.…

8-KJanuary 29, 2026

ResMed ($RMD) board declared a quarterly cash dividend of $0.60/share.

ResMed ($RMD) board declared a quarterly cash dividend of $0.60/share. Record date Feb 12, 2026; ex-dividend date Feb 11, 2026; payable Mar 19, 2026.…

8-KJanuary 29, 2026

ResMed ($RMD) furnished a press release (Exhibit 99.1) on Jan 29, 2026 reporting results for the quarter…

ResMed ($RMD) furnished a press release (Exhibit 99.1) on Jan 29, 2026 reporting results for the quarter ended Dec 31, 2025. Investors: see the release for…